Adverum Biotechnologies Inc.

0.9230+0.0380+4.29%Vol 181.10K1Y Perf 38.11%
Dec 6th, 2023 16:00 DELAYED
BID0.8917 ASK0.9450
Open0.8830 Previous Close0.8850
Pre-Market- After-Market0.89
 - -  -0.03 -3.39%
Target Price
3.67 
Analyst Rating
Strong Buy 1.33
Potential %
297.62 
Finscreener Ranking
★★★+     51.37
Insiders Trans % 3/6/12 mo.
100/100/67 
Value Ranking
★★★     51.33
Insiders Value % 3/6/12 mo.
100/100/10 
Growth Ranking
★+     42.27
Insiders Shares Cnt. % 3/6/12 mo.
100/100/46 
Income Ranking
 —    -
Price Range Ratio 52W %
21.67 
Earnings Rating
Strong Sell
Market Cap93.25M 
Earnings Date
9th Nov 2023
Alpha0.00 Standard Deviation0.26
Beta0.72 

Today's Price Range

0.83000.9450

52W Range

0.53102.34

5 Year PE Ratio Range

-7.30-1.30

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
7.93%
1 Month
-7.35%
3 Months
-49.72%
6 Months
-36.79%
1 Year
38.11%
3 Years
-93.54%
5 Years
-75.48%
10 Years
-

TickerPriceChg.Chg.%
ADVM0.92300.03804.29
AAPL192.32-1.1000-0.57
GOOG131.43-0.9600-0.73
MSFT368.81-3.7150-1.00
XOM99.11-1.3300-1.32
WFC44.500.01000.02
JNJ156.62-1.9300-1.22
FB196.640.99000.51
GE119.81-0.4200-0.35
JPM156.31-1.6600-1.05
ValuationValueIndustryS&P 500US Markets
-0.40
0.31
18.06
242.90
-0.60
-1.17
0.31
2.09
-33 627 700.00
Forward PE-1.07
PEG-
Financial StrengthValueIndustryS&P 500US Markets
7.10
7.50
0.31
0.51
-
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
-
-1 948.30
-1 886.40
-13 415.90
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-48.48
-27.54
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.30-0.33-10.00
Q02 2023-0.32-0.313.12
Q01 2023-0.30-0.293.33
Q04 2022-0.32-0.33-3.12
Q03 2022-0.32-0.40-25.00
Q02 2022-0.38-0.44-15.79
Q01 2022-0.34-0.38-11.76
Q04 2021-0.42-0.3516.67
Earnings Per EndEstimateRevision %Trend
12/2023 QR-0.31-34.78Negative
12/2023 FY-1.24-4.20Negative
3/2024 QR-0.33-43.48Negative
12/2024 FY-0.8212.77Positive
Next Report Date-
Estimated EPS Next Report-0.30
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume181.10K
Shares Outstanding101.03K
Shares Float95.67M
Trades Count1.07K
Dollar Volume163.57K
Avg. Volume279.13K
Avg. Weekly Volume339.76K
Avg. Monthly Volume257.72K
Avg. Quarterly Volume239.92K

Adverum Biotechnologies Inc. (NASDAQ: ADVM) stock closed at 0.885 per share at the end of the most recent trading day (a 0.44% change compared to the prior day closing price) with a volume of 232.46K shares and market capitalization of 93.25M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 114 people. Adverum Biotechnologies Inc. CEO is Laurent Fischer.

The one-year performance of Adverum Biotechnologies Inc. stock is 38.11%, while year-to-date (YTD) performance is 52.72%. ADVM stock has a five-year performance of -75.48%. Its 52-week range is between 0.531 and 2.34, which gives ADVM stock a 52-week price range ratio of 21.67%

Adverum Biotechnologies Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.31, a price-to-sale (PS) ratio of 18.06, a price to cashflow ratio of 242.90, a PEG ratio of -, a ROA of -41.77%, a ROC of -39.93% and a ROE of -62.30%. The company’s profit margin is -%, its EBITDA margin is -1 886.40%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Adverum Biotechnologies Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.30 for the next earnings report. Adverum Biotechnologies Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Adverum Biotechnologies Inc. is Strong Buy (1.33), with a target price of $3.67, which is +297.62% compared to the current price. The earnings rating for Adverum Biotechnologies Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adverum Biotechnologies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adverum Biotechnologies Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.67, ATR14 : 0.08, CCI20 : -23.76, Chaikin Money Flow : -0.03, MACD : -0.05, Money Flow Index : 53.87, ROC : -0.48, RSI : 46.10, STOCH (14,3) : 65.38, STOCH RSI : 1.00, UO : 48.92, Williams %R : -34.62), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adverum Biotechnologies Inc. in the last 12-months were: Fischer Laurent (Sold 41 239 shares of value $32 166 ), Riley Brigit (Sold 7 299 shares of value $5 693 ), Setareh Seyedkazemi (Sold 6 201 shares of value $9 429 ), Soparkar Peter (Sold 13 360 shares of value $10 421 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (83.33 %)
5 (83.33 %)
4 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (16.67 %)
1 (16.67 %)
1 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.33
Strong Buy
1.33
Strong Buy
1.40

Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. The company is committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye, who currently have limited or burdensome treatment options. Its services are focused on advancing three lead gene therapy programs to address unmet needs in wet age-related macular degeneration and in rare diseases alpha-1 antitrypsin deficiency and hereditary angioedema. Its leading programs include ADVM-022, ADVM-043 and ADVM-053.

CEO: Laurent Fischer

Telephone: +1 650 659-9323

Address: 800 Saginaw Drive, Redwood CIty 94063, CA, US

Number of employees: 114

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

58%42%

Bearish Bullish

60%40%

 

News

Stocktwits